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Abstract
Background: Considering the increasing use of polymyxins to treat infections due to multidrug
resistant Gram-negative in many countries, it is important to evaluate different susceptibility testing
methods to this class of antibiotic.
Methods: Susceptibility of 109 carbapenem-resistant P. aeruginosa to polymyxins was tested
comparing broth microdilution (reference method), disc diffusion, and Etest using the new
interpretative breakpoints of Clinical and Laboratory Standards Institute.
Results: Twenty-nine percent of isolates belonged to endemic clone and thus, these strains were
excluded of analysis. Among 78 strains evaluated, only one isolate was resistant to polymyxin B by
the reference method (MIC: 8.0 µg/mL). Very major and major error rates of 1.2% and 11.5% were
detected comparing polymyxin B disc diffusion with the broth microdilution (reference method).
Agreement within 1 twofold dilution between Etest and the broth microdilution were 33% for
polymyxin B and 79.5% for colistin. One major error and 48.7% minor errors were found
comparing polymyxin B Etest with broth microdilution and only 6.4% minor errors with colistin.
The concordance between Etest and the broth microdilution (reference method) was respectively
100% for colistin and 90% for polymyxin B.
Conclusion: Resistance to polymyxins seems to be rare among hospital carbapenem-resistant P.
aeruginosa isolates over a six-year period. Our results showed, using the new CLSI criteria, that the
disc diffusion susceptibility does not report major errors (false-resistant results) for colistin. On
the other hand, showed a high frequency of minor errors and 1 very major error for polymyxin B.
Etest presented better results for colistin than polymyxin B. Until these results are reproduced
with a large number of polymyxins-resistant P. aeruginosa isolates, susceptibility to polymyxins
should be confirmed by a reference method.
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Background
Polymyxins are a multicomponent polypeptide antibiotic
that act primarily on the gram-negative bacterial cell wall,
leading to rapid permeability changes in the cytoplasmic
membrane and ultimately to cell death [1]. The poly-
myxin E named colistin and polymyxin B have been used
to treat several infections caused by multidrug resistant
Pseudomonas aeruginosa (MDR-PA) isolates, which are
resistant to aminoglycosides, cephalosporin and penicil-
lins anti-pseudomonas, quinolones, monobactams and
carbapenem [2,3]. Our hospital has been using polymyx-
ins as a therapeutic option to treat MDR-PA infection
since an outbreak that occurred in 1992 [2,4,5].
Although the availability of less toxic antipseudomonal
antibiotics relegated polymyxins to the status of a reserve
agent, the subsequent development of MDR-PA has made
polymyxins of interest once more, as it possess the advan-
tage of rapid bactericidal activity and only slowly leads to
the development of resistance [3,6,7].
Only in 2005 the National Committee on Clinical Labo-
ratory Standards (NCCLS) now called Clinical and Labo-
ratory Standards Institute (CLSI), approved a standard
document for the testing of polymyxins using dilution
method [8]. However, disc susceptibility testing methods
remain the most commonly used techniques in clinical
microbiology laboratories. Until recently the zone size
interpretations were based on data from literature [9].
Interpretative criteria for disc susceptibility testing of pol-
ymyxin were this current year available from the CLSI
[10]. European guidelines for polymyxin E disc suscepti-
bility testing were also published by the British Society for
Antimicrobial Chemotherapy (BSAC), the Société Fran-
caise de Microbiologie (SFM) and the German Deutsches
Institut fur Normung (DIN) [11,12]. However, there is
not a consensus regarding the breakpoint to define resist-
ance to polymyxins.
Considering the increasing use of polymyxins to treat
infections due to multidrug resistant Gram-negative infec-
tions in many countries, it is important to evaluate differ-
ent susceptibility testing methods to this class of
antibiotic.
In this study, the antimicrobial activities of the polymyx-
ins were evaluated against carbapenem-resistant P. aerugi-
nosa isolated from blood over a six-year period comparing
different assays such as broth microdilution, disc diffu-
sion, and Etest using the new CLSI criteria [10].
Methods
A total of 109 strains of P. aeruginosa isolated from
patients with bloodstream infection (BSI) over a 6-year
period (1998–2003), were identified by Vitek
(BioMérieux) and this identification was confirmed by
classical microbiological testing methods. Carbapenem-
resistance was defined as: isolates resistance to imipenem
or meropenem by broth microdilution susceptibility test-
ing.
2.1 Susceptibility test
Polymyxin B and colistin sulfate powders were obtained
from Sigma Chemical (St. Louis, Mo.). One mg of poly-
myxin B is equivalent to 8,240 units and 1 mg of poly-
myxin E to 19,530 units. The other tested drugs were
obtained commercially or provided by their respective
manufacturers.
Susceptibility to the following antibiotics was determined
by broth microdilution method: imipenem, meropenem,
cephalosporins and penicillins anti-pseudomonas, qui-
nolones, monobactam and aminoglycosides [13]. Poly-
myxins susceptibility testing was performed using disc
diffusion, broth microdilution and Etest (AB Biodisk)
methods. Disc diffusion was done using 10 µg colistin
disc (Oxoid), and 300 U polymyxin B disc (Oxoid). Broth
microdilution with cation-adjusted Muller-Hinton broth
(BBL-Becton Dickinson) was carried out in accordance
with CLSI recommendations and was used as reference
method [8,10]. The same inoculum was used for disc,
Etest and broth microdilution testing. Bacterial suspen-
sions were adjusted according to CLSI recommendations
and the final inoculum was verified for all three suscepti-
bility methods [13]. MIC50 and MIC90 were calculated for
all antibiotics tested.
MICs were also determined by Etest method according to
the manufacturer's guidelines (AB Biodisk, Solna, Swe-
den). MICs of Etest were rounded up to the next higher
twofold dilution. MICs ≥ 8 µg/mL for polymyxin B and
colistin were the breakpoint to designate resistant isolates
for microdilution and Etest methods [14]. Disc zone
diameters were interpreted according to the CLSI for col-
istin (resistant ≤ 10 mm and susceptible ≥ 11 mm) and for
polymyxin B (resistant ≤11 mm and susceptible ≥12 mm)
[10]. Agreement between Etest and microdilution was
defined as MICs that differed by ± 1log2 dilution or less.
Categorical agreement was defined as test results within
the same susceptibility. Errors were ranked as follows:
very major error, false-susceptible result by the disc diffu-
sion test; major error, false-resistant result produced by
the disc diffusion test; and minor error, intermediate
result by disc diffusion method and a resistant or suscep-
tible category for the reference method (microdilution
test). Unacceptable levels are ≥ 1.5% for very major errors,
≥3% for major errors and 10% for minor errors as recom-
mended in CLSI document M23-A2 [15].
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Escherichia coli ATCC 25922 and P. aeruginosa ATCC
27853 were carried out as quality control (QC) strain for
all susceptibility testing methods [10,16].
2.2 Molecular typing
The preparation of chromosomal DNA for PFGE was per-
formed as described elsewhere. Bacterial isolates were
grown on blood agar overnight at 37°C. Gel blocks were
made by using equal volumes of 2% low-melting-point
agar (BioRad) and a bacterial suspension of 9 × 108 cells.
DNA was digested with Spe-I (New England BioLabs) at
37°C for 15 hours. The PFGE was performed with use of
1% agarose gel (BioRad) in a CHEF DRII system (BioRad)
under the following conditions: run time, 20 hours; tem-
perature, 14°C; voltage, 200 V; initial forward time, 5 s;
final forward time 90 s; Lambda concatamers were run in
the first and last lanes. Genotypes were defined on the
basis of DNA banding patterns. Isolates with identical pat-
terns were considered genotypically "indistinguishable",
while those that differed by 1 to 3 bands were defined as
"closely related" and 4 to 6 bands as "possible related".
"Unrelated" or "different" strains referred to those that
differed by ≥7 bands [17].
Results
A total of 109 BSI carbapenem-resistant P. aeruginosa iso-
lates obtained from 93 patients were studied. All isolates
were resistant to imipenem and only two were susceptible
to meropenem (MICs 2.0 µg/mL and 4.0 µg/mL). The col-
istin MIC50 and MIC90 were both 1.0 µg/mL and poly-
myxin B MIC50 and MIC90 were 0.5 and 1.0 µg/mL,
respectively (table 1).
All strains were analyzed by PFGE method. We identified
one endemic clone (clone A) in 29% of these isolates Fig-
ure 1. The clone A isolates were susceptible to both poly-
myxins (MICs ranged from 0.25 to 2.0 µg/mL). The MIC50
and MIC90 for colistin were 1.0 and 2.0 µg/mL, respec-
tively. These isolates had the same value of MIC50 and
MIC90 (1.0 µg/mL) to polymyxin B. So, strains that
belonged to clone A were excluded.
According to the breakpoints for disc diffusion testing by
CLSI[10], 9 (11.5%) isolates were resistant and 69
(88.5%) susceptible to polymyxin B. However, only one
isolate were defined as resistant to polymyxin B by broth
microdilution (MIC 8.0 µg/mL) this strain had a MIC of
2.0 µg/mL to colistin. These results were confirmed by
repeating it three times using the same procedure condi-
tions. For colistin, all strains 78 (100%) were susceptible
by disc diffusion and broth microdilution (Figures 2 and
3). Very major and major error rates of 1.2% and 11.5%
were detected comparing polymyxin B disc diffusion with
the broth microdilution (reference method) and no errors
were detected with colistin.
Agreement within 1 twofold dilution between Etest and
the broth microdilution reference method were 33% for
polymyxin B and 79,5% for colistin. The comparison
between broth microdilution and Etest MICs results for
polymyxin B and colistin are shown in (Figure 4 and 5).
One (1,2%) very major error and 38 (48,7%) minor errors
were found comparing polymyxin B Etest with microdilu-
tion and 5 (6,4%) minor errors with colistin. The cathe-
gorical concordance was respectively 100% for colistin
and 90% for polymyxin B (Table 2). The MICs determined
by broth microdilution testing for the QC strains (E. coli
ATCC 25922 and P. aeruginosa ATCC 27853) were the
same as the range proposed by CLSI. The colistin disc
zone diameters ranged from 15 to 20 mm for the E. coli
ATCC 25922, and varied from 15 to 19 mm for P. aerugi-
nosa ATCC 27853. For polymyxin B disk tests, the QC
ranges were 17 to 20 mm for E. coli and 17 to 22 mm for
P. aeruginosa. The Etest E. coli QC results ranged from 0.25
to 1.0 µg/mL for polymyxin B and from 0.125 to 0.5 µg/
mL for colistin. For P. aeruginosa ATCC 27853 the QC
results were 0.5 to 2.0 µg/mL for both polymyxins tested.
Table 1: Activities of ten agents against 109 isolates of carbapenem-resistant P. aeruginosa isolates obtained from patients with BSI 
over a six-year period.
Agent MIC50 µg/mL MIC90 µg/mL Range µg/mL % Susceptibility
Aztreonam 64 128 1 – >128 7.4
Cefepime 32 128 <0.25 – >128 7.3
Ceftazidime 128 >128 <0.25 – >128 8.3
Ciprofloxacin 32 64 <0.25 – 64 6.4
Colistin 1 1 <0.25 – 2 100
Gentamicin >128 >128 0.5 – >128 20.2
Imipenem 64 256 16 – 1,024 0
Meropenem 32 256 2 – 1,024 1.8
Piperacillin/Tazobactam >128 >128 1 – >128 13.8
Polymyxin B 0.5 1 <0.25 – 8 99.1
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Discussion
Emerging resistance in P. aeruginosa leads to the need for
the parenteral use of polymyxins and reliable susceptibil-
ity methods to predict the clinical response. In this current
year the CLSI recommended a new breakpoint and guid-
ance for disc diffusion and microdilution methods for P.
aeruginosa [10].
Polymyxins resistance among P aeruginosa isolates has
been described in patients with cystic fibrosis, however,
data on acquired resistance to polymyxins among isolates
causing nosocomial infection are scanty [18,19]. The
majority of our isolates remained susceptible to colistin
despite the widely use of this drug in our hospital [4,5].
Only one isolate (1.2%) was resistant to polymyxin B
(MIC 8.0 µg/mL) by broth microdilution method. Two
recent studies in hospitals of New York showed similar
results [20,21]. One study demonstrated that only 5% of
527 P. aeruginosa isolates from 11 hospitals had reduced
susceptibility to polymyxin B with MICs ranging from 4 to
8 µg/mL. However, this study evaluated a short period of
time of three months [20]. The other study did not find
any isolate resistant to polymyxins [21]. The results of our
study reinforce that polymyxins are still a good option to
treat bloodstream infection due to carbapenem-resistant
P. aeruginosa, and that the increase of resistance to poly-
myxins appears to be rare among the isolates from our
hospital.
The disc diffusion technique was reported to be an unreli-
able method for evaluating the susceptibility to polymyx-
ins [9,22]. Despite the recent recommendations of CLSI,
data from Gales and colleagues using other breakpoint
showed that disc diffusion assay for polymyxins are likely
to be used only as a screening test to polymyxins suscepti-
bility. Colistin displayed no good activity against P. aeru-
ginosa isolates (MIC90 4 mg/L) and there were many false-
susceptible results [9]. The accuracy of disc diffusion
assays is unsatisfactory because polymyxins diffuse poorly
into agar and consequently results of a diffusion test
should be confirmed with a dilution method. In a recent
study, the susceptibility to polymyxins of 228 clinical iso-
lates of Acinetobacter sp., P. aeruginosa and Enterobacte-
riaceae was tested by agar dilution and the results were
compared with those obtained by three standardized disc
susceptibility testing methods (CLSI methodology, BSAC
and SFM) [22]. These authors showed that disc diffusion
produced an unacceptably high rate of very major errors
(5–11%). Thus, according to this study disc diffusion
remains an inherently unreliable susceptibility testing
method for polymyxins [22]. Our study is the first one
that used the new interpretative breakpoints for polymyx-
ins recommend by the CLSI [10]. Frequent minors errors
and 01 very major were finding with polymyxin B com-
paring disc diffusion with microdilution (reference
method). Better results, however, were finding using col-
istin.
The breakpoints for polymyxins susceptibility differ
among scientific communities. The SFM specifies that iso-
Table 2: Microdilution and Etest discrepancy rates for polymyxin 
B and Colistin and 78 carbapenem-resistant P. aeruginosa 
isolates.
Antimicrobial 
agents
No. (%) aof discrepancies
Very Major Error Major error Minor
Polymyxin B 1 (1,2%) _ 38 (48,7%)
Polymyxin E _ __ 5 (6,4%)
aUnacceptable levels are show in bold. They are ≥ 3% for major 
errors as recommended in CLSI document M23 [15].
Pulsed-field gel electrophoresis results showing different clones of carbapenem-resistant P. aeruginosa compared with endemic clon  represent d by numb rs 161, 162 and 163Figure 1
Pulsed-field gel electrophoresis results showing different clones of carbapenem-resistant P. aeruginosa compared with endemic 
clone represented by numbers 161, 162 and 163.
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lates with MIC >2 mg/L are considered resistant, while the
BSAC adopts a breakpoint of >4 mg/L [11,12] and the
CLSI published resistance breakpoints of ≥ 8 mg/L for P.
aeruginosa [10]. The comparison of the three methods
should be used cautiously since they differ in various
parameters such as inoculum size and the medium used.
Likewise, pH, anion content, effect of sulphomethyl deriv-
atives comparing with sulphate and others characteristics
can influence the results. The best reference method is not
known and further studies need to address this point.
However, there is a study that showed a good concord-
ance between agar dilution and microdilution [23].
In the literature there are only few studies on the reliabil-
ity of Etest as a method for susceptibility testing for poly-
myxins against Gram-negative. One study suggested that
Etest could be an useful test as a screening method to
detect polymyxin B and colistin resistance among Steno-
trophomonas maltophilia isolates, with an agreement of
96.7% and 89.4%, respectively [24]. However, it showed
a high frequency of major errors.
This is the first study that compared polymyxin B and col-
istin Etest with broth microdilution test (reference
method) to detect susceptibility among carbapenem-
resistant P. aeruginosa using the new breakpoints recom-
mended by CLSI [10]. A recent study compared suscepti-
bility to colistin of 172 isolates of Enterobacteriacae
including 47 isolates of P. aeruginosa using Etest, Vitek and
agar dilution. This study showed 11% of very major error
and 30% of major error with Etest and 30% of very major
errors with Vitek [25]. Goldstein et al [26] evaluated 170
clinical isolates of Gram-negative including a total of 64 P.
aeruginosa (12 colistin-resistant strains) and compared
Etest with agar dilution (reference method) for testing sus-
ceptibility to colistin. MICs of < 4 mg/l were considered to
indicate susceptibility to colistin. Etest showed 91% of
agreement (± 2-fold dilution) in comparison with the ref-
erence method. We observed a different result than these
previous reports. The polymyxin B Etest showed unaccept-
able 38 (48,7%) minor errors and 1 (1,2%) very major
error comparing with the broth microdilution test (the
reference method), whereas colistin Etest had only 5
(6,4%) minor errors. Agreement within 1 twofold dilu-
tion between polymyxin E Etest and the broth microdilu-
tion was 79.5% and concordance of 100%. This result is
similar to those described for Acinetobacter spp. by Arroyo
et al [27], that showed a concordance of 98.2% of colistin
Etest and the reference broth microdilution method, with
only two (1.7%) very major errors.
Comparative results between broth microdilution MICs and 300 U disc zon  diameters for P lymyxin B (PB) tested against 78 carbapenem-re istant P. aeruginosa is latesFigure 3
Comparative results between broth microdilution MICs and 
300 U disc zone diameters for Polymyxin B (PB) tested 
against 78 carbapenem-resistant P. aeruginosa isolates. The 
broken lines represent the breakpoint values for Polymyxin B 
by disc diffusion method [10].
Comparative results between broth microdilution MICs and 10-µg disc zon  diameters for C listin tested against 78 car-bapenem-resistant P. a ruginosa isolatesFigur  2
Comparative results between broth microdilution MICs and 
10-µg disc zone diameters for Colistin tested against 78 car-
bapenem-resistant P. aeruginosa isolates. The broken lines 
represent the breakpoint values for Polymyxin E by disc diffu-
sion method [10].
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A major problem with our study is the collection of strains
used, since they were isolated only in one center and only
01 strain was resistant to polymyxin B. Nevertheless, the
evaluation of clonality showed that only 29% of isolates
belonged to the endemic clone (clone A) previously
reported in our hospital and these strains were excluded of
the comparison of analysis of susceptible methods.
The results of the present study showed using the new
CLSI criteria that the disc diffusion does not report major
errors (false-resistant) results for colistin. On the other
hand, showed a high frequency of minor errors and 1 very
major error for polymyxin B. Etest presented better results
for colistin than polymyxin B. Until these results are
reproduced with a large number of polymyxins-resistant
P. aeruginosa isolates, susceptibility to polymyxins should
be confirmed by a reference method.
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